TrialSite News covered the Merck acquisition of Peloton Therapeutics (Peloton). As the Dallas TX-based venture published an S-1 in anticipation of going public, we offered a brief summary of this venture heavily infused with UT Southwestern-born innovation. In this brief, we provide more detailed information on the transaction and Peloton itself. Merck announced its acquisition of Peloton Therapeutics, a clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2α (HIF-2α) for the treatment of patients with cancer and other non-oncology diseases. Peloton’s lead candidate PT2977, is a novel oral HIF-2α inhibitor in late-stage development for renal cell carcinoma (RCC) (kidney cancer).
Dr. Roger M. Perlmutter, president Merck Research Laboratories stated, “This acquisition exemplifies Merck’s strategy to pursue novel therapeutic candidates based on exceptionally promising and innovative research” and explained, “Peloton scientists have applied their unique expertise in HIF-2α biology to develop PT2977, which has already shown intriguing activity in the treatment of ren...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).